Nonhuman Primate Pilot Grant Program
Vetrinarians from the Division of Veterinary Medicine at TNPRC perform video assisted thoracoscopic surgery on a rhesus monkey. Minimally invasive endoscopic surgery minimizes surgical morbidity and provides for a more rapid recovery when compared to open surgical techniques.
The pilot grant application deadline is December 1, 2015. Here are the application details!
The purpose of this Pilot Grant Program is to facilitate opportunities for investigators from Penn, CHOP, and Wistar to utilize nonhuman primates for studies of AIDS. The Penn CFAR’s Nonhuman Primate (NHP) Core based at the Tulane National Primate Research Center (TNPRC) provides animals (typically rhesus macaques) and support for these studies. The goal of this program is to enable investigators to acquire sufficient data that can be applied for future external funding.
Funds are available for the procurement and care of 8 non-human primates a year (up to 4 animals per project), and provide support for appropriate animal laboratory studies including collection of body fluids, biopsies, surgeries, necropsies and basic laboratory studies for simian (SIV) or simian/human (SHIV) immunodeficiency virus research. From 1 to 3 projects per year will be funded, depending on the number of animals requested, the length of the project, and receipt of competitive applications. Laboratory studies performed at Penn/CHOP/Wistar will be the responsibility of the investigator. There are no funds available for salary support.
Investigators from Penn, CHOP, and Wistar are eligible for this Pilot Program. Junior investigators and HIV/AIDS investigators with no previous experience using the non-human model are particularly encouraged to apply.
If interested, it is required that all applicants contact one of the investigators (listed below) from the Tulane National Primate Research Center as early as possible to discuss potential studies, study design, and availability of animals.
Although applications in all areas of HIV/AIDS research are eligible, areas of particular interest include those related to SIV and SHIV pathogenesis, SIV or SHIV reservoirs, models for viral eradication and functional cure, vaccines, and addictions research.
No budget page is required as the award is for procurement/use of animals at TNPRC.
|Dr. Andrew A. Lackner
|Dr. Preston Marx
|Dr. Ron Veazey
Previous Nonhuman Primate Pilot Projects
|Year||Investigator||Title of Project|
|2012||David Allman, Ph.D.||Long-lived plasma cells in non-human primates|
|2012||Michael P. Cancro, Ph. D., Jean L. Scholz, Ph.D.||Manipulating BLyS as a strategy for relaxing B cell selection to reveal neutralizing specificities in nonhuman primates|
|2011||Sita Awasthi, Ph.D., Harvey Friedman, M.D.||Evaluation of Immunogenicity and efficacy of a HSV-2 trivalent vaccine in macaque model of HSV-2 vaginal infection|
|2011||Beatrice Hahn, M.D., Nick Parrish||Transmissibility of a SIVmac239 Mutant with increased Env content|
|2011||George Shaw, M.D., Ph.D.||Hypermutation in the 5' Untranslated Region (5' UTR) of SIVmac 251/239: A Novel Mechanism of Virus Containment and Escape|
|2010||James Hoxie, M.D.||In vivo studies of a novel CD4-independent variant of SIVmac239|
Una O'Doherty, Ph.D.,
|SIV Reservoir Size and Location in Chinese Rhesus Macaques Progressors and Nonprogressors|
|2010||John Wherry, Ph.D.,
|T-bet-dependent regulation of CD8 T cell exhaustion and PD-expression during SIV infection|
|2009||Robert Doms, M.D., Ph.D.||Zinc finger nuclease-mediated disruption of HIV-1 coreceptors|
|2009||Dennis Kolson, M.D., Ph.D. Francisco Gonzalez-Scarano, M.D.||Oral dimethyl fumarate (BG-12), Funaderm?, an immune modulator and novel candidate central nervous system (CNS) neuroprotectant against SIV/HIV|
|2008||Ronald Collman, M.D.||Gut Microbial Modification in SIV Immune Activation|
|2008||Fred Frankel, Ph.D.||Intranasal Challenge|
|2008||Samuel Parry, M.D. and Preston Marx, Ph.D.||Heterosexual Transmission of HIV: The Uterus as a Critical Target|
|2007||Jean Boyer, Ph.D.||The Impact of Parasitic Infection on AIDS Vaccines|
|2007||Dennis Kolson, M.D., Ph.D. and Kelly Jordan-Sciutto, Ph.D.||The Integrated Stress Response (ISR) in SIV Neuropathogenesis|
|2007||Elena Perez, M.D., Ph.D. and Carl June, M.D.||NHP CCR5 ZFNs Proof of Concept|
|2006||Frederic Bushman, Ph.D.||Lentiviral Infection and Dynamics of the Gut Microbial Flora|
|2005||Luis Montaner, D.V.M., D.Phil. and Andrew Lackner, D.V.M., Ph.D.||TALL-104 Cell Inhibition of SIV Infection|
|2005||David B. Weiner, Ph.D.||Directing Lymphoid Compartments by DNA Vaccines|
|2004||Steven D. Douglas, M.D.||Pilot Study of the Safety, Tolerability, and Pharmacokinetics of Aprepitant, a Neurokinin-1R Receptor Antagonist, in Uninfected and SIV-infected Rhesus Macaques|
|2004||Drew Weissman, Ph.D.||Analysis of Viral and Immune Response in Lymph Nodes of Virologically Suppressed SIV-infected Macaques|